OBJECTIVE:To investigate whether peritumoral electroacupuncture (EA) suppresses tumor growth viaCD8+ T cell infiltration mediated by sympathetic nervous system (SNS) regulation. METHODS:Utilizing a mouse model of triple-negative breast cancer (TNBC), the SNS was activated through chronic restraint stress (CRS); chemical sympathetic denervation was induced by 6-hydroxydopamine (6-OHDA). The anti-tumor and immune regulatory effects of EA were evaluated by multidimensional methods, including in vivobioluminescence imaging, flow cytometry, immunofluorescence, and enzyme-linked immunosorbent assay. RESULTS:Peritumoral EA decreased the volume and weight of tumors within 22 d after the implantation. Intratumoral CD8+ T cells significantly increased after EA. C-C motif chemokine ligand 5, as a chemokine that recruits effector T cells to the tumor microenvironment, also up-regulated. Meanwhile, EA reduced intratumoral sympathetic innervation and norepinephrine level. Subsequently, we found CRS significantly accelerates tumor growth and reduces the density of CD8+ T cell infiltration. However, EA reversed the tumor-promoting effect and immune suppression caused by CRS effectively. Furthermore, chemical sympathetic ablation with 6-OHDA revealed that the anti-tumor effect of EA was dependent on sympathetic integrity, as the ablation impaired both tumor-suppressing effect and CD8+ T cell recruitment mediated by EA. CONCLUSION:EA enhances anti-tumor immunity through SNS emphasizing the effective remodeling of the tumor immune microenvironment in mice with TNBC by neuro-immune interactions.

Triple-negative breast cancer (TNBC) is known for its aggressive nature and poor prognosis, primarily due to limited treatment options stemming from immune evasion mechanisms. This study aimed to explore the therapeutic potential of peritumoral electroacupuncture (EA) in inhibiting tumor growth in TNBC, particularly focusing on the immune mechanisms related to CD8+ T cell recruitment and the involvement of histone deacetylase 1 (HDAC1) within the tumor microenvironment (TME). By constructing TNBC model in mice, we observed that EA not only inhibited tumor growth but also increased the presence of intratumoral CD8+ T cells and CCL5. Additionally, the expression of HDAC1 was found to down-regulate by EA. Remarkably, when EA was combined with the romidepsin (a class I HDAC inhibitor), a synergistic effect observed, leading to a greater increase in intratumoral CD8+ T cells compared to either treatment alone, resulting in a tumor inhibition rate of 60.03%. Importantly, EA did not worsen systemic inflammation, as serum levels of pro-inflammatory cytokines remained stable throughout the intervention. These findings indicate that peritumoral EA can effectively enhance anti-tumor immunity within the TME by down-regulating HDAC1. This research highlights the potential of combining non-invasive therapies like EA with pharmacological agent as a promising strategy for improving outcomes in the management of TNBC, warranting further exploration of its clinical applications.

顽固性贝尔面瘫的康复治疗是临床实践中的难题.通过对古今医籍的梳理,总结出顽固性贝尔面瘫病在经筋,与肝、脾密切相关,核心病机以气血不足为本、风痰瘀互结为标.基于经筋理论,以经筋辨治为主,运用局部选穴配合远端取穴的针灸疗法治疗.基于气血不足、气痰瘀胶结的病机,采用中药(补阳还五汤加减)治疗.针灸联合中药,互补为用,标本兼顾,在促进顽固性面瘫患者功能恢复中具有重要作用.

OBJECTIVE To investigate the effect of the decoction of Fuzheng Jiedu Xiaoji formula (, FJXF) plus chemoembolization (TACE) on primary liver cancer (PLC) in patients, and study the underlying mechanism. METHODS Patients with PLC who met the inclusion criteria were randomized into case group and control group. The case group was treated with FJXF combined with TACE. The control group was treated with TACE alone. The short-term clinical effect was evaluated; liver biochemistry, liver function index and multidrug resistance-associated indicators were detected. RESULTS FJXF combined with TACE in the case group significantly increased the disease control rate than TACE alone in the control group (83.3% 61.1%). There was a reduction in the serum alpha-fetoprotein at 8 weeks after treatment in each group, while no difference between the two groups. The same trend can be observed for transaminase and direct bilirubin in both groups. In the case group, it showed a significant increase for albumin at 8 weeks after treatment, while no change in the control group. Multidrug resistance-associated indicators for multidrug resistance protein 1 and p-glycoprotein were upregulated in the case group but remained stable in the control group. CONCLUSIONS FJXF combined TACE had a better short-term effect than TACE alone in patients with PLC. The potential mechanism was probably associated with alleviated multidrug resistance induced by FJXF. Additionally, FJXF didn't increase the risk of liver damage in the combined therapy.

Purpose: The aim of this study was to investigate the anti-tumor effect of electroacupuncture (EA) on mice bearing breast tumors by regulating p75 neurotrophin receptor (p75NTR) and remodelling intratumoral innervation. Methods: Female BALB/c mice were implanted with 4T1 breast tumor cells to establish a murine mammary cancer model. Tumor volume and weight were measured to evaluate tumor growth. Cell apoptosis was assessed by TUNEL assay. The relative expression of p75NTR, TrkA, TrkB, NGF and proNGF were detected by immunohistochemistry. Neurotransmitter and neurotrophin were detected by enzyme-linked immunosorbent assay. Intratumoral innervation was confirmed by beta 3-tubulin and TH labeling immunohistochemistry. The antagonist TAT-Pep5 was employed to determine if the effects of EA on tumor growth and cell apoptosis were mediated by p75NTR. Results: Peritumoral EA alleviated tumor growth especially after 14 days of intervention. Apoptosis index in the tumor tissue was obviously decreased after EA. Meanwhile, EA intervention significantly upregulated the expression of p75NTR and proNGF, along with a decline in the tumor growth and an increase in the cell apoptosis. Besides, EA reduced local sympathetic innervation and downregulated sympathetic neurotransmitter NE level in the local tumor. Furthermore, p75NTR antagonist alleviated EA-mediated cell apoptosis and intratumoral innervation. Conclusions: One mechanism of EA intervention for alleviating tumor progression is mediated by p75NTR to promote apoptosis and decrease intratumoral axonogenesis in the tumor microenvironment.

Traditional Chinese herbal medicine has a long history in treating febrile diseases, according to the Shang Han Lun, a classical theory of traditional Chinese medicine (TCM) developed by Zhang Zhongjing in the Han Dynasty. Some herbs have been formulated as prescription formulae or manufactured as finished medicines such as pills, capsules, or injections. The Chinese government has recommended specific TCM prescriptions alone or combined with Western medicine to treat patients with coronavirus disease 2019 (COVID-19). Here, we introduce three prescription formulae: Qingfei Paidu decoction, Huashi Baidu formula, and Xuanfei Baidu formula; three finished medicines: Lianhua Qingwen capsules, Jinhua Qinggan granules, and Xuebijing injection; and several single herbs, such as Ephedra Herba, honeysuckle, Scutellaria, Glycyrrhizae Radix, Armeniacae Semen, Sophorae flavescentis Radix, and Curcuma longa. We review existing evidence on these traditional medicines and herbs for their related antiviral activities, efficacy, and underlying mode of action in virus-related diseases. Most of these drugs have been traditionally used in Chinese medicine for over a thousand years, and they have been proved to be safe in treating flu-like virus infections. It is necessary to further test their efficacy for treating COVID-19 and understand the underlying molecular mechanisms.

甲状腺结节是临床常见病、多发病,黄金昶教授经过20余年临床实践总结,认为甲状腺结节的形成和少阳功能异常密切相关,少阳为气机升降出入的枢纽,内寄相火,是水液运行的通道.少阳枢机不利,气、火、痰、瘀壅结颈部是甲状腺结节形成的基本病机.在治疗中采用定位疏剿法治疗本病,分为一疏二调三剿;一疏为疏通局部经络郁滞,包括:刺络祛瘀疏通经络;针刺解结疏通经络;颈浅针刺横向疏通颈关;二调:左升右降通调少阳气机;三剿:结节围刺,加强针刺力量,同时结合辨证选穴治疗,临床上多获良效.

目的 系统评价艾灸治疗恶性肿瘤化疗后引起的白细胞减少症的疗效.方法 通过全面检索中国知网、万方、维普、Pubmed、Wed of Science等数据库中发表的艾灸治疗化疗引起的白细胞减少症临床随机对照试验文献,用Cochorane系统评价方法,依据纳入、排除标准筛选文献、整理资料,采用Rev Man5.4软件进行质量评价和Meta分析.结果 最终纳入18篇.Meta分析显示艾灸治疗化疗后白细胞减少症较常规升白药物疗效好,差异有统计学意义.结论 艾灸治疗化疗后白细胞减少症的疗效较好,操作方便,值得推广.

Background: Long non-coding RNAs (lncRNAs) play an important role in the immune processes of glioma. Immune related lncRNAs (IRlncRs) may be a critical prognosis in patients with glioma. The current study aimed to construct a glioma immune-related prognosis model by IRlncRs. Methods: Transcriptome RNA-sequencing data of glioma were obtained from The Cancer Genome Atlas (TCGA) and an immune‑related risk score (IRRS) model was constructed by Lasso and multivariate Cox regression analysis. Receiver Operating Characteristic (ROC) curves were used to assess the sensitivity and specificity of the prognosis on IRRS. A predictive nomogram and a time-dependent ROC curve was performed in training and validation cohort. We explored the relationships between survival‑related IRlncRs (sIRlncRs) and clinicopathologic parameters. Functional annotation of the sIRlncRs was investigated by gene set enrichment analysis (GSEA) and principal component analysis (PCA). The relationships between IRRS model and immune cell infiltration and co-expression network analysis among the sIRlncRs were performed for molecular mechanism study. Results: A total of 10 sIRlncRs were enrolled to build IRRS model. The IRRS was identified as an independent prognostic factor and correlated with the overall survival (AUC =0.880). The nomogram was constructed successfully with IRRS, age and grade as variables. Immune cell infiltration analysis indicated that B cells, neutrophil, dendritic and macrophage cells were positively correlated with IRRS. PCA and GSEA illustrated that the lncRNA signature enrolled the IRRS model was closely related to immune status. Additionally, co-expression network showed that there was a strong correlation between 10 sIRlncRs at the transcriptional level. Conclusion: We successfully constructed a remarkable clinical model of sIRlncRs with potential prognostic value for glioma patients, which provides an insight into immunological research and treatment strategies of glioma.

目的 评价艾灸对放化疗患者淋巴细胞及其亚群影响的临床疗效,为指导临床应用提供证据.方法 在中国知网(CNKI)、中国学术期刊数据库(万方数据库)、中国科技期刊数据库(维普)、中国生物医学文献数据库(SinoMed)、PubMed、Cochrane图书馆等数据库,检索艾灸治疗恶性肿瘤患者的随机对照临床试验(Randomized Controlled Clinical Trails,RCTs),日期截止至2019年12月,由2名单独研究者进行数据提取及循证方法学质量评价,并应用RevMan 5.3软件进行数据分析,二分类变量数据结果采用相对危险度(RR)来分析效应量,连续性变量数据结果则采用平均差(MD)表示,区间估计用95％CI.结果 纳入14篇RCTs,治疗后试验组CD3+、CD4+淋巴细胞计数、NK细胞计数及CD4/CD8+比值较对照组升高,差异有统计学意义,结果分别为(MD=5.27,P＜0.00001,95％ CI[3.76～6.79];MD=3.96,P＜0.00001,95％CI[3.01～4.91];MD=5.74,Z=3.58,P=0.0003,95％ CI[2.60～8.88];MD=3.96,P＜0.00001,95％ CI[3.01～4.91]).CD8+淋巴细胞亚群计数比较,差异无统计学意义(MD=-1.01,P=0.44,95％ CI[-3.59～1.57]).试验组患者KPS评分较对照组升高,差异有统计学意义(MD=9.57,P=0.007,95％CI为[2.61～16.53]).由于纳入文献整体质量偏低,异质性较高,倒漏斗图提示可能存在发表偏倚.结论 艾灸可升高恶性肿瘤患者淋巴细胞及其亚群计数,提高其KPS评分,能够保护机体免疫功能,提高患者生活质量.受纳入研究整体质量影响,尚需设计严谨、报告规范的高质量临床研究进一步证实.

Traditional Chinese herbal medicine has a long history in treating febrile diseases, according to the Shang Han Lun, a classical theory of traditional Chinese medicine developed by Zhang Zhongjing in the Han Dynasty. Some herbs have been formulated as prescription formulae or manufactured as finished medicine such as pills, capsules or injections. The Chinese government has recommended specific TCM prescriptions alone or combined with Western medicine to treat patients with COVID-9. Here, we introduce three prescription formulae, Qingfei Paidu Decoction, Huashi Baidu Formula, and Xuanfei Baidu Formula, three finished medicines, Lianhua Qingwen Capsule, Jinhua Qinggan Granule, and Xuebijing Injection; following this, several single herbs such as Ephedra herba, Honeysuckle, Scutellaria, Glycyrrhizae radix, Armeniacae semen, Sophorae flavescentis radix, and Curcuma longa. We review existing evidence of these traditional medicines and herbs for their related antiviral activities, efficacy, and underlying mode of action in virus-related diseases. Most of these drugs have been traditionally used in Chinese medicine for over a thousand years, and they have been proved to be safe in treating flu-like virus infections. It will be adequate to further test for their efficacy for COVID-19 and understand the underlying molecular mechanism.

Evidence is mounting to indicate that cancer patients may have more likelihood of having coronavirus disease 2019 (COVID‐19) but lack consistency. A robust estimate is urgently needed to convey appropriate information to the society and the public, in the time of ongoing COVID‐19 pandemic. We performed a systematic review and meta‐analysis through a comprehensive literature search in major databases in English and Chinese, and two investigators conducted publication selection and data extraction independently. A meta‐analysis was used to obtain estimates of pooled prevalence of cancer in patients with COVID‐19 and determine the association of cancer with severe events, after assessment of potential heterogeneity, publication bias, and correction for the estimates when necessary. Total 38 studies comprising 7094 patients with COVID‐9 were included; the pooled prevalence of cancer was estimated at 2.3% (95% confidence limit [CL] [0.018, 0.029]; P < .001) overall and 3.2% (95% CL [0.023, 0.041]; P < .001) in Hubei province; the corresponding estimates were 1.4% and 1.9% after correction for publication bias; cancer was significantly associated with the events of severe cases (odds ratio [OR] = 2.20, 95% CL [1.53, 3.17]; P < .001) and death (OR = 2.97, 95% CL [1.48, 5.96]; P = .002) in patients with COVID‐19, there was no significant heterogeneity and a minimal publication bias. We conclude that cancer comorbidity is associated with the risk and severe events of COVID‐19; special measures should be taken for individuals with cancer.

目的 运用网络药理学研究半夏泻心汤治疗胃癌的物质基础与潜在作用机制.方法 基于多源在线数据库收集半夏泻心汤化学成分集,筛选化学活性成分,运用化学相似性找靶,垂钓半夏泻心汤潜在靶点,同时通过多源在线数据库整合的方法获取胃癌的相关靶点,匹配半夏泻心汤、胃癌靶点,选取重合的靶点作为半夏泻心汤治疗胃癌的关键靶点,将虚拟筛选的靶点进行GO富集分析及相关信号通路注释,采用Cytoscape软件构建网络.结果 收集半夏泻心汤953种化学成分,筛选出164种有效成分,前五位的活性成分为β-谷甾醇、豆甾醇、槲皮素、谷甾醇、山奈酚,与胃癌靶点关联度较强的分别为槲皮素、山奈酚、β-谷甾醇、吴茱萸次碱、黄柏酮.获取83个重合靶点,GO富集分析预测半夏泻心汤治疗胃癌主要涉及细胞凋亡、细胞增殖、肿瘤微环境和机体内环境四个方面.通过KEGG获取23条信号通路,其中PI3K-Akt、MAPK、NF-kappa B可能是其发挥抗肿瘤癌作用的主要通路.结论 预测半夏泻心汤通过参与增殖、凋亡、神经内分泌免疫等机制发挥抗胃癌作用,其物质基础可能是β-谷甾醇、槲皮素、山奈酚.

Abstract Background: N6-methyladenosine (m6A) methylation modification can affect the tumorigenesis, progression, and metastasis of breast cancer (BC). Up to now, a prognostic model based on m6A methylation regulators for BC is still lacking. This study aimed to construct an accurate prediction prognosis model by m6A methylation regulators for BC patients.Methods: After processing of The Cancer Genome Atlas (TCGA) datasets, the differential expression and correlation analysis of m6A RNA methylation regulators were applied. Next, tumor samples were clustered into different groups and clinicopathologic features in different clusters were explored. By univariate Cox and Least Absolute Shrinkage and Selection Operator (LASSO) analysis, m6A regulators with prognostic value were identified to develop a prediction model. Furthermore, we constructed and validated a predictive nomogram to predict the prognosis of BC patients.Results: 19 m6A related genes were extracted and 908 BC patients enrolled from TCGA dataset. After univariate Cox and LASSO analysis, 3 m6A RNA methylation regulators (YTHDF3, ZC3H13 and HNRNPC) were selected to establish the prognosis model based on median risk score (RS) in training and validation cohort. With the increasing of RS, the expression levels of YTHDF3 and ZC3H13 were individually elevated, while the HNRNPC expressed decreasingly. By survival analysis and Receiver Operating Characteristic (ROC) curve, we found that the overall survival (OS) of high-risk group was significantly shorter than that of the low-risk group based on Kaplan-Meier (KM) analysis in each cohort. Univariate and multivariate analysis identified the RS, age, and pathological stage are independent prognostic factors. A nomogram was constructed to predict 1- and 3-year OS and the calibration plots validate the performance. The C-index of nomogram reached 0.757 (95% CI:0.7-0.814) in training cohort and 0.749 (95% CI:0.648-0.85) in validation cohort, respectively.Conclusions: We successfully constructed a predictive prognosis model by m6A RNA methylation regulators. These results indicated that the m6A RNA methylation regulators are potential therapeutic targets of BC patients.

吞咽困难是食管癌常见的临床症状,主要表现为进食梗噎、呛咳等,目前缺乏有效的治疗方法.黄金昶教授在临床上善用金津玉液刺血治疗食管癌导致的吞咽困难,舌下静脉点刺放血可以疏通任脉气血,促进气血、津液的正常输布,改善病变食管局部瘀血、痰浊、气滞等病理状态,促进食管的蠕动,从而缓解吞咽困难症状.文章总结吞咽困难的病因病机、金津玉液刺血的作用机制、操作细节及适应证,为临床治疗食管癌患者的吞咽困难提供新的思路与方法.

化疗药物引起的外周神经毒性是临床常见的药物不良反应之一,目前缺乏行之有效的治疗手段.黄金昶教授20余年中医肿瘤临床积累了丰富的经验,认为气血不足、外邪侵袭是本病的核心病机,通过内外治结合手段达到快速祛邪通络、养血温阳的治疗目的,采用局部与整体治疗相结合的方法,取得了较好效果.

Malignant pleural effusion (MPE) is one of the common complications of tumor. Acupuncture-moxibustion therapy has several advantages for treatment of MPE. Acupuncture is regarded as a complex individualized intervention, and its characteristics of TCM is difficult to be reflected by strict randomized controlled trials. The registry study provides more possibilities for the data collection of individualized diagnosis and treatment under the guidance of the overall concept and syndrome differentiation, and is more suitable for data management and collection of large samples and multi-center trials in the real-world study. It has become an opportunity to carry out real-world study of acupuncture for MPE. There are many challenges in the registry study of acupuncture for MPE. However, it is of great significance to collect real-world data of acupuncture for MPE to improve the clinical effect of MPE and provide a new clinical research method for acupuncture in tumors and related complications.

膜系泛指人体体腔内外广泛分布的固有结缔组织所构成的系统,是人体气水火布散通道,具有运行津血、协调脏腑、联络筋骨、沟通表里等作用.文章主要通过对中医膜系的认识、募穴的探究及恶性胸腔积液的形成等方面从中医膜系角度探讨黄金昶教授通过针刺募穴为主的方案治疗恶性胸腔积液的作用机制,为中医临床治疗恶性胸腔积液以及相关科研提供理论参考.

"癌毒"是肿瘤发生、发展过程中的重要致病因素之一,以毒攻毒为常用的抗肿瘤大法,然有毒中药的毒性反应限制了其临证运用.壁虎为常用以毒攻毒中药,同时具有化痰逐瘀、祛风通络之效,适用于多种肿瘤,淋巴转移瘤疗效尤为突出.运用壁虎等有毒中药治癌,不仅要明辨药物性味功效和肿瘤核心病机,还应严格把控有毒中药的治疗剂量,全面了解毒性反应及减毒方法,以便在临证中安全有效地运用以毒攻毒法.

Coronavirus Disease 2019 (COVID-19), a new respiratory disease caused by severe acute respiratory syndrome virus 2, has emerged as an ongoing pandemic and global health emergency. This article primarily aims to describe laboratory tests, comorbidities, and complications, specifically comprise 1) the incubation period and basic epidemiological parameters, 2) clinical manifestations, 3) laboratory tests, including routine blood tests, inflammatory biomarkers, cardiac biomarkers, liver and renal function, and blood coagulation function, 4) chest imaging features, 5) significant comorbidities and complications. This information on the disease conditions would help dissect the disease heterogeneity for appropriately selecting clinical treatment strategies and therapeutic development.